Table 2 Best overall response to everolimus treatment
From: Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
Best overall response, n (%) | N = 57 |
|---|---|
Complete response | 5 (8.8) |
Partial response | 21 (36.8) |
Stable disease | 20 (35.1) |
Progressive disease | 9 (15.8) |
Unknown | 2 (3.5) |